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Background: Polycystic kidney disease (PKD), a genetic disorder characterized by multiple cysts and renal failure at
an early age. In children, kidney disease is often accompanied by disordered mineral metabolism, failure to achieve
peak bone mass, and reduced adult height. Optimizing bone health during the growth stage may preserve against
bone loss associated with early renal dysfunction in PKD. Dietary soy protein and omega-3 polyunsaturated fatty
acid (n-3 PUFA) have been reported to ameliorate PKD and to promote bone health. The study objective was to
determine the bone effects of feeding soy protein and/or n-3 PUFAs in a rat model of PKD.
Methods: Weanling female PCK rats (n = 12/group) were randomly assigned to casein + corn oil (Casein + CO),
casein + soybean oil (Casein + SO), soy protein isolate + soybean oil (SPI + SO) or soy protein isolate + 1:1 soybean
oil:salmon oil blend (SPI + SB) for 12 weeks.
Results: Rats fed SPI + SO diet had shorter (P = 0.001) femur length than casein-fed rats. Rats fed SPI + SO and
SPI + SB diet had higher (P = 0.04) calcium (Ca) and phosphorus (P) retention. However, there were no significant
differences in femur and tibial Ca, P or bone mass between diet groups. There were also no significant difference
in bone microarchitecture measured by micro-computed tomography or bone strength determined by three-point
bending test between diet groups.
Conclusions: Early diet management of PKD using SPI and/or n-3 PUFAs influenced bone longitudinal growth and
mineral balance, but neither worsened nor enhanced bone mineralization, microarchitecture or strength.
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Kidney disease in children is often accompanied by disor-
dered mineral metabolism, decreased adult height, and
failure to achieve peak bone mass (PBM) [1,2]. Epidemio-
logical studies demonstrated greater incidence of bone
fracture in end stage renal disease patients [3]. Worldwide,
the third most common cause of renal failure is polycystic
kidney disease which is characterized by multiple cysts,
massive enlargement of the kidneys, and loss of renal* Correspondence: janet.tou@mail.wvu.edu
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unless otherwise stated.function [4]. In autosomal dominant polycystic kidney dis-
ease (ADPKD), the most prevalent inherited form of poly-
cystic kidney disease, individuals are asymptomatic until
the third or fifth decades of life [5]. In the rarer autosomal
recessive polycystic kidney disease (ARPKD), disease onset
occurs early with more than 50% of affected children pro-
gressing to renal failure in the first decade of life [5,6].
Common strategies for the management of renal disease
in childhood include maintaining a healthy body weight
and maximizing PBM [7].
Soy protein isolate (SPI) and omega-3 polyunsaturated
fatty acids (n-3 PUFAs) are dietary components reported
in pre-clinical studies to ameliorate polycystic kidney
disease progression and severity [7]. The PCK rat, anThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pre-clinical testing of drug treatments [8]. To our know-
ledge no studies have investigated the effects of dietary
SPI on PCK rats. The PCK rat is derived from a spon-
taneous mutation in Sprague–Dawley rats [9]. Growing
female Sprague–Dawley rats fed SPI have been reported
to have enhanced bone mineral content (BMC) and
bone mineral density (BMD) compared to casein [10].
Some potential bone protective effects of SPI are the
presence of estrogenic isoflavones and an amino acid
profile associated with reduced acid load [11]. Diet acid
load is a major determinant of calcium (Ca) excretion
and in turn, bone mineral loss [11].
Different n-3 PUFA sources also affect bone. Growing
female Sprague–Dawley rats fed fish oil rich in the long-
chain n-3 PUFAs, eicosapentaenoic acid (EPA, 20:5n-3)
and docosahexaeonic acid (DHA, 22:6n-3), increased
long bone BMD and BMC compared to rats fed corn oil
low in n-3 PUFAs [12]. Growing female Hans:SPRD-cy
rats, a non-orthologous model of human ADPKD, fed
ALA-rich flaxseed oil had higher whole body BMC and
BMD compared to animals fed corn oil [13]. To our
knowledge no studies have investigated whether dietary
n-3 PUFAs enhances bone health in ARPKD.
Studies on the effects of ARPKD on bone are lacking
because treatment priority is on slowing disease progres-
sion to renal failure and early mortality [7]. Some drug
therapies in development to treat polycystic kidney dis-
ease have reported side effects that include bone loss
[14]. Also, many drugs used in the treatment of osteopor-
osis are not approved for use in patients with moderate to
advanced kidney diseases [3]. Early diet management by
optimizing bone health during the growth stage can po-
tentially minimize bone loss due to renal dysfunction at
an early age in polycystic kidney disease patients. There-
fore, the objective of this study was to determine whether
feeding growing female PCK rats SPI and n-3 PUFA can
affect mineral balance and optimize bone health. Female
rats were used because they are reportedly more efficient
at metabolizing dietary ALA to the bioactive n-3 PUFAs,
EPA and DHA [15]. Female Hans:SPRD-cy rats fed diets
supplemented with phytoestrogens had more beneficial ef-
fects on PKD progression than male rats [16]. Also, slower
progression of PKD in females enable the subtle influence
of diet to be detectable [7].
Methods
Animals and diets
All animal procedures were conducted in accordance with
the Institute of Laboratory Animal for the Care and Use of
Laboratory Animals Guidelines [17], and were approved by
the Animal Care and Use Committee at West Virginia
University. Growing (age 28 d) female PCK rats were
purchased from Charles River Laboratories (Wilmington,MA). All rats were kept in a 21°C room with a 12 hour
light/dark cycle throughout the 12 week study period. Fol-
lowing a 7- day acclimation period, animals were randomly
assigned (n = 12 rats/group) to experimental diets. A power
analysis conducted prior to the experiment showed that
with 10 rats/group at an alpha = 0.05 there is 80% power
to detect a difference in BMD and bone volume per unit
of total volume (BV/TV) between the diet groups. An
additional 2 rats/group was included due to possibility of
morbidity or mortality due to disease severity in PCK rats.
All experimental diets were manufactured by Harlan
Teklad (Madison, WI). Diet ingredients are provided in
Table 1. The experimental diets were based on the
American Institute of Nutrition-93G (AIN-93 G) standard
rodent diet consisting of purified ingredients formulated
to meet all the nutritional requirements of growing rats as
defined by the National Research Council [18]. The AIN-
93G diet is formulated with casein as the protein source
(200 g/kg diet) and soybean oil as the lipid source (70 g/kg
diet). In this study, experimental diets consisted of either
casein or SPI as the protein source. SPI was generously
provided by DuPont Nutrition and Health (St. Louis,
MO). Both protein sources consisted of 87% crude pro-
tein. Caloric value was 4.3 kcal/g for SPI and 4.2 kcal/g
for casein.
The lipid sources consisted of corn oil because it is
high in n-6 PUFA and low in n-3 PUFA which is typical
of Western diets [19]. Soybean oil was included because
it contains both essential fatty acids, the n-6 PUFA, lino-
leic acid (LA, 18:2n-6) and the n-3 PUFA, ALA. A 1:1
ratio of soybean oil:salmon oil was included because it
contains the n-3 PUFAs, ALA, EPA and DHA. Salmon oil
was purchased from JEdwards International Inc (Quincy,
MA). Caloric value was 9.2 kcal/g for corn oil, 9.1 kcal/g
for soybean oil, and 9.3 kcal/g for the 1:1 soybean oil:sal-
mon oil blend.
The experimental diets consisted of: 1) casein + corn
oil (Casein + CO), 2) casein + soybean oil (Casein + SO),
3) soy protein isolate + soybean oil (SPI + SO) or 4) soy
protein isolate + 1:1 soybean/salmon oil (SPI + SB). Cal-
oric value was 3.77 Kcal/g and metabolizable energy was
16.1 ± 0.3 kJ/g for all diets. Using inductively coupled
plasma spectrometry (ICP, model P400, Perkin Elmer,
Shelton, CN), dietary Ca content was determined to be
higher (P = 0.04) in the SPI + SO (9.7 ± 0.1 mg/g) and
SPI + SB (10.4 ± 0.1 mg/g) compared to Casein + SO
(8.8 ± 0.1 mg/g) and Casein + CO (8.2 ± 0.2 mg/g) diets.
Dietary phosphorus (P) content was determined to be
higher (P = 0.03) in the SPI + SO (7.3 ± 0.1 mg/g) and
SPI + SB (7.2 ± 0.1 mg/g) compared to Casein + SO (6.1 ±
0.5 mg/g) and Casein + CO (6.5 ± 0.2 mg/g) diets.
All diets were kept at −20°C until fed. Rats were pro-
vided their assigned diet and deonized distilled water
(ddH2O) to prevent mineral intake from sources other
Table 1 Experimental diet composition
Ingredient (g/kg diet)1 Casein + CO Casein + SO SPI + SO SPI + SB
Casein 200.0 200.0 0.0 0.0
Soy protein isolate 0.0 0.0 200.0 200.0
L-Cystine 3.0 3.0 1.3 1.3
Corn Starch 397.5 397.5 397.5 397.5
Maltodextrin 132.0 132.0 132.0 132.0
Sucrose 100.0 100.0 100.0 100.0
Soybean Oil 70.0 0.0 70.0 35.0
Corn Oil 0.0 70.0 0.0 0.0
Salmon Oil 0.0 0.0 0.0 35.0
Cellulose 50.0 50.0 50.0 50.0
Mineral Mix2 35.0 35.0 35.0 35.0
Vitamin Mix2 10.0 10.0 10.0 10.0
Choline bitartrate 2.5 2.5 2.5 2.5
TBHQ, antioxidant 0.014 0.014 0.014 0.014
Calories 377 377 377 377
Fatty acids (% total fatty acids)
n-3 PUFAs
Alpha-linolenic acid (ALA, 18:3n-3) 0.59 ± 0.18c 7.69 ± 0.02a 7.68 ± 0.04a 4.85 ± 0.01b
Eicosapentaenoic acid (EPA, 20:5n-3) ND ND ND 7.4 ± 0.03
Docosahexaenoic acid (DHA, 22:6n-3) ND ND ND 3.9 ± 0.1
n-6 PUFAs
Linoleic acid (LA, 18:2n-6) 52.93 ± 2.68a 55.78 ± 0.07a 56.09 ± 0.09a 35.19 ± 0.06b
Arachidonic acid (ARA, 20:4n-6) 1.10 ± 0.04a 0.16 ± 0.005c 0.21 ± 0.01c 0.41 ± 0.007b
n-3/n-6 0.01 0.14 0.14 0.44
1All ingredients are from Harlan Teklad except for SPI from DuPont Nutrition and Health (St. Louis, MO) and salmon oil from JEdwards International (Quincy, MA).
2Based on the AIN-93G vitamin and mineral mixes [36]. Different superscript letters a, b, c within the same rows indicate significant differences at P < 0.05 by
one-way ANOVA followed by Tukey’s test. Abbreviations are CO corn oil, SO soybean oil, SPI soy protein isolate, SB 1:1 soybean oil:salmon oil blend, TBHQ tertiary
butylhydroquinone, ND not detectable.
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throughout the 12 week study.
Mineral balance
To prevent variability in food intake, rats were provided
15 ± 2 g of powdered diet daily. This amount has been
reported to support growth based on body weights [20].
Food intake was measured daily and replaced with fresh
diet. During the final week of the 12 weeks feeding study,
rats were individually housed in metabolic cages to collect
urine and feces. Final 7 day urine samples were collected,
centrifuged at 1,500 g for 10 min at 4°C, filtered through
Whatman no. 1 paper, and diluted 1:10 in ddH2O. Urinary
Ca and P concentration were determined using ICP
(model P400, Perkin Elmer, Shelton, CN).
Diet and fecal samples were freeze-dried for 48 h,
ashed in a muffle furnace at 550°C for 24 h, and then
acidified in 70% nitric acid. The acidified samples were
neutralized in ddH2O, filtered through Whatman no. 1paper, diluted 1:50 in ddH2O, and both diet and fecal Ca
and P content determined by ICP.
Following euthanasia by CO2 inhalation, the chest cav-
ity was opened and the aorta punctured to collect blood.
Blood was centrifuged at 1,500 g for 10 min at 4°C to ob-
tain serum. Serum samples were stored at −80°C until
assayed. Serum parathyroid hormone (PTH) was deter-
mined by commercially available rat enzyme immunoassay
(EIA) kit (RayBiotech Inc., GA). Absorbance was deter-
mined at 450 nm using a Spectramax Plus microplate
reader (Molecular Devices, Sunnyvale, CA). Serum Ca and
P were determined enzymatically using a commercially
available Vet-16 rotor and quantified by a Hemagen Ana-
lyst automated spectrophotometer (Hemagen Diagnostics
Inc., Columbia, MD).
Bone morphometry
Following euthanization by CO2 asphyxiation, the right and
left femurs and tibiae were collected (n = 12 rats/group).
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medial lateral width, anterior posterior width, and length
were determined using a vernier caliper (Bel-Art Products,
Pequannock, NJ). Length was measured from the medial
condyle to greater trochanter. Bones were dried at 110°C
for 48 h then weighed using an analytical balance (Mettler
Toledo, Columbus, OH). Morphometry measurements
were averaged for bone pairs (i.e. right and left) after no bi-
lateral differences were determined using paired t-test with
significance level set at P < 0.05.
Bone densitometry, Ash, Ca, and P
Dual energy X-ray absorptiometry (DXA) scans (Hologic
QDR 4500-A Elite) were performed on the left bones.
Tibial and femoral specimens were placed in Millipore
water. Bone mineral area (BMA), BMC, BMD were eval-
uated from all scans using the Regional High Resolution
software package designed for studying isolated bone
specimens (Hologic Waltham, MA).
Following DXA, bones were ashed in a muffle furnace
(model CP18210, Thermolyne, Dubuque, IA) at 600°C
for 24 h then weighed. Bone ash was dissolved in 2 mL
of 70% nitric acid. Acidified samples were filtered through
Whatman no. 1 paper and diluted (1:500 v/v) to volume
with ddH2O. Bone Ca and P content were measured
using ICP.
Bone microarchitectural analyses
Trabecular and cortical bone architecture was determined
in the left bones using micro-computed tomography (μCT)
(MicroCT40, SCANCO Medical, Switzerland). Cortical
bone architecture was evaluated on a 512 μm region of the
femur and tibia mid-diaphysis. Cortical indices included
cortical thickness, cortical area, medullary area, and poros-
ity. The trabecular bone within the distal femur metaphysis
and proximal tibial metaphysis were scanned and 200 im-
ages (~16 μm/slice or 3.2 mm) were analyzed with semi-
automatically drawn contours beginning 400 μm from the
growth plate including only secondary spongiosa within
the volume of interest. The volume of interest was assessed
for structural parameters included trabecular BV/TV, tra-
becular number (TbN), trabecular thickness (TbTH), tra-
becular separation (TbSp), trabecular connectivity (Conn),
and structure model index (SMI). All scans were per-
formed utilizing a 1024 × 1024 matrix resulting in an iso-
tropic voxel resolution of 22 μm3. An integration time of
70 milliseconds per projection was used with a rotational
step of 0.36° resulting in total acquisition time of approxi-
mately ~150 min/sample.
Bone biomechanical strength
Bone strength indices were assessed using a TA.XT2i
Texture Analyzer (Texture Technologies, Scarsdale, NY)
outfitted with a three-point bending apparatus. Femoraand tibiae were placed on supports and force applied on
the medial surface of the bones by lowering a centrally
placed blade (1 mm width) at a constant crosshead
speed (0.1 mm/sec) until the bone was broken. The load
cell was 250 kg. The load-deflection data were collected
by a PC interfaced with the TA.XT2i. Sample test dis-
tance was set at 10 mm with a signal collection rate of
100 points per sec. A force-displacement curve gener-
ated from the biomechanical test was used to determine
bone strength measurements. Peak force is the highest
load obtained before bone fracture occurs. Ultimate stiff-
ness is the slope of the curve responding to bone stiffness
[21]. Ultimate bending stress is a normalized calculated
force that takes into account the size of the bone and
Young’s Modulus is a normalized calculated bone stiffness
that takes into account bone size [22].
Bone turnover markers
Serum osteocalcin concentration was determined using
a commercially available rat specific EIA (Biomedical
Technologies, Stoughton, MA). Urinary deoxypyridino-
line (DPD) concentration was determined by commer-
cially available EIA kit (Quidel Corporation, CA). Serum
osteocalcin was measured at 450 nm and urinary DPD
was measured at 405 nm using a Spectramax Plus mi-
croplate reader.
Statistical analysis
Results are expressed as means ± standard error of the
mean (SEM). One way analysis of variance (ANOVA)
was used to determine differences between treatment
groups. Post-hoc multiple comparisons were performed
using Tukey’s test (parametric) or Wilcoxon rank test
(non-parametric). Differences were considered significant
at P < 0.05. All statistical analyses were performed using
SigmaStat 3.1 statistical software program (Systat Software
Inc., San Jose, CA).
Results
Body Weight and Bone Morphometry
Growing female PCK rats fed different dietary treat-
ments for 12 weeks had similar body weights (Figure 1).
Femur length was shorter (P = 0.001) in PCK rats fed
SPI + SO diet compared to rats fed Casein + CO and
Casein + SO diets (Table 2). There were no significant
differences in femur width or dry weight between any of
the diet groups. There were no differences in tibia length,
width, and dry weight.
Mineral intake and balance
Urinary output was higher (P = 0.01) in rats fed SPI diets
compared to rats fed casein diets, but there were no dif-
ferences (P = 0.79) in water intake. Ca intake was signifi-
cantly higher in rats fed SPI diets compared to rats fed
Figure 1 The effect of feeding growing PCK female rats soy protein isolate and/or omega-3 polyunsaturated fatty acids on body
weight during the 12 week feeding study. Values are the mean ± SEM of n = 12 rats/diet group. Abbreviations are casein + corn oil (Casein +
CO), casein + soybean oil (Casein + SO), soy protein isolate + soybean oil (SPI + SO) or soy protein isolate + 1:1 soybean/salmon oil (SPI + SB).
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(P = 0.02) in rats fed SPI + SO diets compared to rats fed
casein diets. Rats fed SPI diets had higher (P = 0.04) Ca
retention than rats fed casein diets. There was no signifi-
cant differences in fecal Ca excretion or Ca apparent ab-
sorption between diet groups (Table 3).
P intake was significantly higher in rats fed SPI diets
compared to rats fed casein diets. However, urinary P
excretion was lower (P = 0.01) in rats fed SPI diets com-
pared to rats fed casein diets. Rats fed SPI diets had
higher (P = 0.04) P retention than rats fed casein diets.
There were no significant differences in fecal P excretion
or P apparent absorption between diet groups (Table 3).
There were no significant differences in serum PTH, Ca
or P concentrations among the dietary groups.
Bone mineral analyses
Shown in Table 4, there were no significant differences
in femur or tibial Ca and P between diet groups. Add-
itionally, there were no significant differences in longTable 2 Bone morphometry in growing female PCK rats fed d
Measurement* Casein + CO Casein +
Femur
Length (mm) 31.01 ± 0.13a 31.23 ± 0.1
Medial Lateral width (mm) 3.77 ± 0.02 3.75 ± 0.03
Anterior posterior width (mm) 2.78 ± 0.03 2.77 ± 0.03
Dry weight (g) 0.69 ± 0.04 0.70 ± 0.04
Tibia
Length (mm) 36.24 ± 0.15 36.45 ± 0.0
Medial Lateral width (mm) 2.24 ± 0.02 2.29 ± 0.02
Anterior posterior width (mm) 2.68 ± 0.02 2.67 ± 0.02
Dry weight (g) 0.47 ± 0.02 0.48 ± 0.02
*Values are the means ± SEM of n = 12 rats/group. Different superscript letters a, b w
ANOVA followed by Tukey’s test. Abbreviations are CO corn oil, SO soybean oil, SPIbone ash, BMA, BMC, and BMD between rats fed Ca-
sein + CO, Casein + SO, SPI + SO, and SPI + SB diets.Bone microarchitecture
Shown in Table 5, there were significant differences in
femur or tibia trabecular microarchitecture measurements
of BV/TV, TbN, TbTH, TbSp, Conn or SMI in growing fe-
male PCK rats fed Casein + CO, Casein + SO, SPI + SO,
and SPI + SB diets.
There were also no significant differences in femur or
tibia cortical thickness, cortical area, medullary area or
porosity in growing female PCK rats fed different diets
(Table 6).Bone biomechanical strength
There was no significant difference in femur or tibia
biomechanical strength measures of peak force, ultimate
stiffness, ultimate bending stress, and Young’s Modulus
between the different diet groups (Table 7).ifferent diets
SO SPI + SO SPI + SB P-value
5a 30.17 ± 0.28b 30.74 ± 0.14ab 0.001
3.78 ± 0.02 3.79 ± 0.03 0.78
2.75 ± 0.03 2.84 ± 0.03 0.22
0.68 ± 0.46 0.68 ± 0.04 0.98
7 36.20 ± 0.07 36.17 ± 0.11 0.25
2.24 ± 0.02 2.29 ± 0.02 0.18
2.67 ± 0.02 2.66 ± 0.02 0.88
0.46 ± 0.02 0.47 ± 0.02 0.95
ithin the same rows indicate significant differences at P < 0.05 by one-way
soy protein isolate, SB 1:1 soybean oil:salmon oil blend.
Table 3 Calcium and phosphorus balance in growing female PCK rats fed different diets
Measurement* Casein + CO Casein + SO SPI + SO SPI + SB P-value
Water intake (mL/d) 14.4 ± 9.4 15.2 ± 13.7 16.3 ± 11.5 16.5 ± 12.3 0.79
Urinary Output (mL/d) 2.1 ± 0.2b 2.3 ± 0.2b 3.8 ± 0.3a 3.5 ± 0.3a 0.01
Fecal Output (mg/d) 5.2 ± 0.3 5.0 ± 0.3 5.5 ± 0.3 5.7 ± 0.2 0.21
Calcium
Ca Intake (mg/d) 131.3 ± 2.4b 123.0 ± 2.2b 144.7 ± 2.1a 156.6 ± 2.4a <0.001
Urinary Ca Excretion (mg/mL)1 1.9 ± 0.3a 1.6 ± 0.5a 0.5 ± 0.07b 1.3 ± 0.3ab 0.02
Fecal Ca Excretion (mg/d) 29.9 ± 2.3 27.2 ± 2.3 26.0 ± 2.2 29.0 ± 2.7 0.65
Ca Apparent Absorption (%)2 77.2 ± 1.7 77.9 ± 1.9 82.0 ± 1.5 81.5 ± 1.7 0.12
Ca Retention (mg/d)3 75.7 ± 1.7b 76.6 ± 1.8b 81.7 ± 1.5a 80.6 ± 1.7a 0.04
Phosphorus
P Intake (g) 91.8 ± 1.0b 97.0 ± 2.1b 109.8 ± 2.0a 108.6 ± 2.3a <0.001
Urinary P Excretion (mg/mL)4 7.9 ± 1.0a 6.8 ± 1.3a 3.4 ± 0.6b 2.3 ± 0.6b 0.01
Fecal P Excretion (mg/d) 26.1 ± 2.6 28.4 ± 1.3 28.3 ± 2.5 26.3 ± 2.7 0.85
P Apparent Absorption (%)5 71.6 ± 2.9 70.7 ± 1.4 74.2 ± 2.3 75.7 ± 2.5 0.42
P Retention (mg/d)6 63.0 ± 3.1b 63.7 ± 1.8b 71.1 ± 2.5a 73.6 ± 2.3a 0.04
Serum parathyroid hormone (pg/mL) 36.2 ± 4.1 37.2 ± 4.4 39.9 ± 5.2 43.6 ± 5.9 0.74
Serum Ca (mg/mL) 0.12 ± 0.004 0.12 ± 0.001 0.11 ± 0.004 0.11 ± 0.004 0.17
Serum P (mg/mL) 0.12 ± 0.006 0.13 ± 0.007 0.11 ± 0.006 0.12 ± 0.005 0.32
*Values are expressed as the mean ± SEM of n = 12 rats/group. Different letters a, b within the same column indicate significant differences at P < 0.05 by one-way
ANOVA followed by Tukey’s test. Abbreviations are SO soybean oil, SPI soy protein isolate, SB 1:1 soybean oil:salmon oil blend, Ca calcium; P phosphorus.
1Urinary calcium excretion was calculated as urinary Ca concentration/urine volume.
2Calcium apparent absorption was calculated as [(Ca intake – fecal Ca excretion)/Ca intake] x 100.
3Calcium retention was determined by calculating [Ca intake – (fecal Ca excretion + urinary Ca excretion)].
4Urinary phosphorus excretion was calculated as urinary P concentration/urine volume.
5Phosphorus apparent absorption was calculated as [(P intake – fecal P excretion)/P intake] x 100.
6Phosphours retention was determined by calculating [P intake – (fecal P excretion + urinary P excretion)].
Table 4 Bone mineralization in growing female PCK rats fed different diets
Measurement* Casein + CO Casein + SO SPI + SO SPI + SB P-value
Femur
Ca (mg/g of bone) 93.0 ± 1.0 90.7 ± 1.7 94.3 ± 0.7 94.0 ± 1.5 0.23
P (mg/g of bone) 50.1 ± 0.5 49.0 ± 0.9 50.5 ± 0.4 50.5 ± 0.7 0.39
Ash (mg/g bone) 612.0 ± 7.3 578.9 ± 9.6 601.3 ± 8.2 614.5 ± 8.4 0.66
BMA (cm2) 1.30 ± 0.01 1.29 ± 0.02 1.28 ± 0.01 1.30 ± 0.01 0.27
BMC (g) 0.23 ± 0.0001 0.23 ± 0.0002 0.22 ± 0.0001 0.23 ± 0.0001 0.67
BMD (mg/cm2) 0.18 ± 0.0001 0.18 ± 0.0002 0.17 ± 0.0001 0.18 ± 0.0002 0.35
Tibia
Ca (mg/g of bone) 90.7 ± 1.2 93.0 ± 1.1 96.8 ± 2.5 95.5 ± 1.9 0.14
P (mg/g of bone) 46.8 ± 0.9 48.3 ± 0.6 49.9 ± 1.3 49.5 ± 1.0 0.12
Ash (mg/g bone) 602.5 ± 5.9 592.1 ± 7.8 603.0 ± 7.5 606.7 ± 4.1 0.59
BMA (cm2) 1.54 ± 0.04 1.50 ± 0.06 1.56 ± 0.06 1.49 ± 0.04 0.56
BMC (g) 0.33 ± 0.01 0.32 ± 0.01 0.33 ± 0.01 0.31 ± 0.02 0.48
BMD (mg/cm2) 0.21 ± 0.002 0.21 ± 0.003 0.21 ± 0.001 0.21 ± 0.002 0.68
*Values are the means ± SEM of n = 12 rats/group. Abbreviations are CO corn oil, SO soybean oil, SPI soy protein isolate, SB 1:1 soybean oil:salmon oil blend,
BMA bone mineral area, BMC bone mineral content, BMD bone mineral density, Ca calcium, P phosphorus.
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Table 5 Trabecular bone microarchitecture in growing female PCK rats fed different diets
Measurement* Casein + CO Casein + SO SPI + SO SPI + SB P-value
Femur
BV/TV (%) 14.30 ± 0.54 14.00 ± 0.58 12.95 ± 0.96 13.64 ± 0.86 0.61
TbN (per mm) 2.87 ± 0.11 2.74 ± 0.11 2.77 ± 0.20 2.86 ± 0.10 0.87
TbTh (mm) 0.07 ± 0.0009 0.07 ± 0.001 0.06 ± 0.001 0.07 ± 0.002 0.18
TbSp (mm) 0.36 ± 0.01 0.38 ± 0.01 0.40 ± 0.04 0.36 ± 0.01 0.65
Conn (1/mm3) 80.77 ± 2.99 76.47 ± 2.83 77.06 ± 5.26 77.83 ± 3.59 0.86
SMI 2.28 ± 0.03 2.30 ± 0.05 2.12 ± 0.06 2.36 ± 0.07 0.31
Tibia
BV/TV (%) 9.43 ± 0.62 9.67 ± 0.63 9.13 ± 0.84 9.24 ± 0.83 0.96
TbN (per mm) 2.51 ± 0.13 2.44 ± 0.17 2.39 ± 0.19 2.61 ± 0.16 0.82
TbTh (mm) 0.06 ± 0.001 0.06 ± 0.0009 0.06 ± 0.001 0.06 ± 0.001 0.33
TbSp (mm) 0.42 ± 0.02 0.44 ± 0.30 0.46 ± 0.05 0.41 ± 0.03 0.63
Conn (1/mm3) 43.00 ± 4.56 43.58 ± 4.59 43.53 ± 6.11 43.26 ± 6.34 1.00
SMI 2.85 ± 0.05 2.80 ± 0.04 2.88 ± 0.07 2.88 ± 0.07 0.72
*Values are expressed as the mean ± SEM of n = 12 bones/group. Abbreviations are CO corn oil, SO soybean oil, SPI soy protein isolate, SB 1:1 soybean oil:salmon
oil blend, BV/TV trabecular bone volume per unit of total volume, TbN trabecular number, TbTh trabecular thickness, TbSp trabecular space, Conn connectivity,
SMI structure model index.
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There were no significant differences in serum osteocalcin
(Figure 2A) and urinary DPD concentration (Figure 2B) in
growing female PCK rats fed the different experimental
diets.
Discussion
Hyperphosphatemia, hypocalcemia and hyperparathyr-
oidism in children with chronic renal failure plays a sig-
nificant role in bone disorders [1]. Liver disease can also
contribute to bone disorders through impaired vitamin
D synthesis which results in decreased Ca absorption
and a compensatory increase in PTH production [23].
Despite greater (P = 0.01) urine output in the absence of
higher water intake, urinary Ca excretion was significantlyTable 6 Cortical bone microarchitecture in growing female PC
Measurement* Casein + CO Casein + SO
Femur
Cortical Thickness (mm) 0.55 ± 0.008 0.55 ± 0.004
Cortical Area (mm2) 4.49 ± 0.03 4.40 ± 0.05
Medullary Area (mm2) 0.26 ± 0.006 0.25 ± 0.007
Porosity (%) 5.42 ± 0.12 5.45 ± 0.15
Tibia
Cortical Thickness (mm) 0.52 ± 0.004 0.53 ± 0.003
Cortical Area (mm2) 2.90 ± 0.03 2.94 ± 0.03
Medullary Area (mm2) 0.20 ± 0.004 0.19 ± 0.003
Porosity (%) 6.32 ± 0.02 6.06 ± 0.09
*Values are expressed as the mean ± SEM of n = 12 bones/group. Abbreviations are
oil:salmon oil.lower in rats fed SPI + SO diet compared to rats fed casein
diets. Similarly, urinary P excretion was lower (P = 0.01) in
SPI than casein-fed rats. Higher dietary Ca and P content
in SPI diets resulted in greater Ca and P consumption.
Lower urinary excretion and higher intake resulted in
greater (P = 0.04) Ca and P retention in SPI-fed rats. PTH
decreases Ca and P excretion in the urine; however, in the
current study there were no statistical differences in serum
PTH concentration among the diet groups. Failing kidneys
lose capacity to concentrate urine. Plischke et al. [24]
showed evidence linking fluid intake, vasopression, and
osmotic control in PKD progression. In our study, re-
duced urinary Ca and P excretion in rats fed SPI diet may
be due to lower urinary osmolality. Growing female PCK
rats fed SPI + SO and SPI + SB diet had impaired renalK rats fed different diets
SPI + SO SPI + SB P value
0.56 ± 0.004 0.55 ± 0.004 0.47
4.56 ± 0.03 4.52 ± 0.05 0.06
0.25 ± 0.006 0.26 ± 0.007 0.94
5.28 ± 0.14 5.39 ± 0.12 0.78
0.53 ± 0.01 0.53 ± 0.006 0.59
2.88 ± 0.05 2.98 ± 0.04 0.29
0.18 ± 0.004 0.19 ± 0.005 0.46
6.11 ± 0.13 6.04 ± 0.16 0.37
CO corn oil, SO soybean oil, SPI soy protein isolate, SB 1:1 soybean
Table 7 Bone strength measurements in growing female PCK rats fed different diets
Measurement* Casein + CO Casein + SO SPI + SO SPI + SB P value
Femur
Peak Force (N) 37.2 ± 2.6 42.5 ± 2.7 40.4 ± 2.6 44.5 ± 3.0 0.26
Ultimate Stiffness (N/S) 437.6 ± 23.3 437.7 ± 37.1 385.6 ± 33.7 429.4 ± 29.8 0.63
Ultimate Bending Stress (N/mm2) 41.8 ± 3.2 47.3 ± 2.3 45.7 ± 3.0 48.6 ± 3.5 0.40
Young’s Modulus (N/mm2) 1160.6 ± 54.0 1171.5 ± 106.2 1040.0 ± 100.6 1117.8 ± 99.2 0.75
Tibia
Peak Force (N) 19.2 ± 1.3 22.3 ± 1.7 20.0 ± 1.7 20.7 ± 1.3 0.57
Ultimate Stiffness (N/S) 178.0 ± 13.1 171.3 ± 13.0 158.9 ± 7.9 161.2 ± 10.9 0.61
Ultimate Bending Stress (N/mm2) 51.5 ± 3.4 61.7 ± 4.0 56.37 ± 5.58 57.41 ± 5.26 0.5
Young’s Modulus (N/mm2) 1938.8 ± 166.7 1970.0 ± 172.8 1815.6 ± 125.1 1765.5 ± 150.5 0.76
*Values are expressed as the mean ± SEM of n = 12 bone pairs/group. Abbreviations are CO corn oil, SO soybean oil, SPI soy prtein isolate, SB 1:1 soybean oil:
salmon oil blend.
Maditz et al. BMC Nephrology  (2015) 16:13 Page 8 of 11function indicated by elevated serum blood urea nitrogen
concentration compared to casein-fed rats [25]. Rats fed
SPI + SB diet had significantly more renal cortical cyst ob-
struction [25] as well as significantly higher serum alkaline
phosphatase and bilirubin concentrations due to hepatic
cyst obstruction of the bile duct [26].Figure 2 The effect of feeding growing PCK female rats on soy prote
weight for 12 weeks on A) serum osteocalcin concentration and B) ur
SEM of n = 10 rats/diet group. Abbreviations are casein + corn oil (Casein +
oil (SPI + SO) or soy protein isolate + 1:1 soybean/salmon oil (SPI + SB).Despite higher Ca and P retention there were no dif-
ferences on long bone Ca and P content in SPI com-
pared to casein-fed rats. There were also no differences
in femur or tibial BMA, BMC, and BMD as determined
by DXA. In contrast, feeding growing female Sprague–
Dawley rats SPI for 14 days enhanced tibial BMC andin isolate and/or omega-3 polyunsaturated fatty acids on body
inary deoxypyridinoline concentration. Bars represent the mean ±
CO), casein + soybean oil (Casein + SO), soy protein isolate + soybean
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to a disease versus non-disease state. Also, metabolic
abnormalities accompanying renal disease effects on
bone microarchitecture cannot be detected by DXA
[27]. Using μCT technology, we found no significant dif-
ferences in femur and tibia trabecular microarchitecture
in growing female PCK rats fed different diets. Lukas et al.
[12] reported that growing female Sprague–Dawley rats
fed oil sources rich in ALA increased femur and tibia BV/
TV, TbN, TbTH and reduced TbSp by promoting bone
formation indicated by higher serum osteocalcin concen-
tration and no significant difference in bone resorption. In
the present study, growing female PCK rats fed soybean
oil or soybean oil: fish oil blend showed no significant dif-
ferences in serum osteocalcin or urinary DPD concentra-
tion compared to rats fed corn oil. In our study, soybean
oil was provided as a source of ALA, whereas in the Lukas
et al. [12] study, flaxseed oil was used. The ALA content
of flaxseed oil is higher 57% [20] than soybean oil (7.69%)
or soybean:salmon oil blend (4.85%). Also, a higher dose
(12% wt) of pure flaxseed oil or fish oil was provided to
Sprague–Dawley rats compared to the oil dose (7% wt)
provided to PCK rats. Therefore, higher n-3 PUFA doses
may be necessary to enhance trabecular bone microarchi-
tecture in growing female PCK rats. High fat diets were
not fed to PCK rats due to potential to worsen polycys-
tic kidney disease progression and severity [28]. Also,
hypertension and cardiovascular defects are frequent
complications of PKD that need to be considered when
recommending a high fat diet [29-31]. In children with
chronic kidney disease, cardiovascular disease is the
most common cause of death and this has been sug-
gested to be due in part to dysregulation of Ca and P
homeostasis causing vascular calcification [32]. We did
not assess vascular calcification, but found no signifi-
cant differences in serum PTH, Ca or P concentration
between diet groups.
In kidney disease, elevated PTH has been reported to
preferentially cause cortical bone loss [27,33]. In the
present study, no significant differences in femur and
tibia cortical bone microarchitecture were observed in
growing female PCK fed diets containing different pro-
tein and lipid sources. Growing female Sprague–Dawley
rats fed oils rich in ALA, EPA, and/or DHA also showed
no effect on cortical bone microarchitecture [12]. As ex-
pected in the absence of significant differences in bone
mass and microarchitecture there were no significant dif-
ferences in bone strength measurements between growing
female PCK rats fed different diets.
Besides mineral imbalance and failure to achieve PBM,
children with kidney disease also suffer growth disturbances
[34]. Early management is required to prevent growth fail-
ure and shorter stature [2]. In the present study, all diets
supported growth indicated by no significant differences inbody weights. A long-term (two years) study showed no dif-
ference in body weight gain in Sprague–Dawley rats fed a
soy protein compared to a casein-based diet [35]. Similar
body weight gain has also been reported for growing rats
fed soybean oil, flaxseed oil, and fish oil [20,36]. Hans:
SPRD-cy rats provided soy protein ad libitum had higher
body weights and showed improved kidney cyst volume
and renal function compared to rats fed casein [37]. In our
study female PCK rats fed SPI diets showed higher final
urinary output and decreased renal function compared to
casein-fed rats; however, there were no significant body
weight differences. This may have been because all diets
were restricted to 15 g/d.
In our study, femur length was shorter in rats fed SPI +
SO diet compared to rats fed casein diets. SPI contains
isoflavone phytoestrogens with binding specificity for es-
trogen receptor beta [38]. Estrogen receptor beta has been
shown to be a physiological inhibitor of bone growth [39].
Tou et al. [40] reported that female Sprague–Dawley rats
fed a phytoestrogen diet shortened (P < 0.05) femur length
compared to rats fed a casein diet. However, PCK rats fed
SPI + SB diet had no effect on femur length. The type of
lipid associated with SPI may influence bone. Of the diet
groups, SPI + SB diet consisting of a soybean oil:fish oil
blend had the highest n-3:n-6 PUFA ratio as well as EPA
and DHA content. Growing female Hans:SPRD-cy rats, a
model of ADPKD, fed casein with 7% wt ALA-rich flax-
seed oil for 12 weeks resulted in longer femurs compared
to rats fed corn oil low in ALA [41]. ALA can be con-
verted to EPA and DHA de novo [42]. Although conver-
sion is inefficient, higher amounts of ALA associated with
flaxseed oil can result in higher EPA and DHA content.
Mechanisms whereby n-3 PUFAs have been suggested to
promote bone growth include reducing prostaglandin E2
production by decreasing the n-6 to n-3 PUFA ratio and
by increasing circulating insulin-like growth factor binding
protein to promote growth factors [43,44]. Estrogen can
simulate the conversion of ALA into their longer-chain
metabolites [45]. Therefore, a potential synergistic effect
of SPI and n-3 PUFAs is estrogenic effects of isoflavones
associated with SPI may increase conversion of ALA to
long-chain n-3 PUFAs. Female PCK rats fed soybean oil
with protein source provided as either SPI or casein
showed no significant differences in serum and liver EPA,
DHA, and ARA content [25,26]. However, dietary groups
in our study did not allow us to specifically assess syner-
gistic effects of protein and n-3 PUFAs on femur longitu-
dinal growth.
Another limitation of this study was the AIN-93G diet
is based on a purified casein diet. This standard purified
diet does not meet the NRC recommendations for sulfur
amino acids to support rodent growth and requires the
addition of L-cysteine [46]. Therefore, SPI diets were
supplemented with L-cysteine to equal casein diets. This
Maditz et al. BMC Nephrology  (2015) 16:13 Page 10 of 11potentially alters acid load typically associated with the
amino acid profiles of these proteins. Also, a longer study
duration than 12 weeks may be required to detect dietary
effects of enhance bone mineralization due to higher Ca
and P retention. However, ARPKD onset occurs early in
childhood with renal failure frequently occurring in the
first decade of life [6]. Although, the PCK rat model has
the advantage of being a slow progressing form of ARPKD,
the study was ended at 12 weeks due to morbidity associ-
ated with severity of polycystic liver [26,47].
Conclusion
In summary, to our knowledge this was the first study
to investigate diet as a therapeutic strategy aimed at
bone health in PCK rats, an orthologous model of hu-
man ARPKD [8,47]. Current general dietary guidelines
to promote a healthier population include increasing
consumption of plant proteins and n-3 PUFAs [48].
Growing female PCK rats fed SPI diets increased Ca
and P retention, but not bone Ca and P content. All di-
ets equally supported body weight gain and produced
no greater or worse long bone mass, microarchitecture,
and strength, but femur longitudinal growth was affected.
Based on the results dietary SPI and n-3 PUFA supple-
mentation influenced mineral balance without enhancing
bone health in ARPKD.
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